Over 80 curators are shaping the direction of the conference with their vision and leveraging their industry credibility to build momentum, jointly laying the content foundation for an Eastern home ground.

 

The soul of a conference lies not in its scale, but in its agenda; the depth of its agenda lies not in the topics, but in who defines the topics.

 

China's new drug circle has no shortage of conferences. What it lacks is a forum where true innovators at the industry's forefront personally design the content, define the boundaries of discussion, and control the quality of output. CPIC 2026 offers a different answer: TONACEA invites the definers of the tracks to become special session curators.

 

Over 80 curators are shaping the direction of the conference with their vision and leveraging their industry credibility to build momentum, jointly laying the content foundation for an Eastern home ground.

 

July, Shanghai · National Exhibition and Convention Center. TONACEA's "Great Power New Drugs" Global Conference – when those who best understand the battle begin to build the stage, the only thing you need to do is take your seat.

 

The curation team is ready. Early bird tickets are available at a limited-time 30% discount. We look forward to welcoming you.

 

Guiding Institutions: Shanghai Biomedical Science and Technology Industry Promotion Center, Shanghai Innovative Drug R&D Center, Shanghai Global Health Innovation Institute
Organizer: TONACEA
Co-organizer: Shanghai National Industry-Education Integration Innovation Center (in preparation)
Strategic Partners: Fudan University School of Biotechnology, Fangda Partners, Ernst & Young, WuXi AppTec, WuXi Biologics, Tofflon, China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)

 

Scan the QR code to register now! Limited-time early bird tickets at 30% off – grab yours now!!

 

 

The Curation Team 

 

Main Forum: The Global Journey of Chinese Innovative Drugs

• Cheng Zengjiang: Founder of TONACEA, Executive Chair of CPIC 2026

• Wu Xiaobin (David Wu): Initiator of the China Innovative Drug Commercialization 50 Forum, President and COO of BeiGene

• Lyu Mingfang: Founding Chair of the China Healthcare Investment 50 Forum, Partner of FountainVest Partners, former Chairman of Shanghai Pharmaceutical Group

 

Frontier Technologies for Chinese New Drugs

 

CNS Innovative Drug R&D Session

• Guo Fei: Scientific Advisor, Hanshu Bio

• Yuan Dawei: Founder, Chairman and General Manager, Beijing Quark Pharma Group

• Shen Huaqiong (Joan Shen): Founder and CEO, NeuShen Therapeutics

 

ATMP & CGT Globalization Session

• Zhang Jinhua: Chairman and CEO, IASO Biotherapeutics

 

Gene Therapy Innovation Session

• Liu Xiao: Vice President, Xingcheng Bio; Chief Brand Officer, TONACEA

• Cai Yuan: Head of AAV, Metabolic Health Lab, Shanda Network

• Gao Lu: CEO, Youyin Bio

 

Stem Cell & Regenerative Medicine New Technologies Session

• Zhang Yu: Co-President, Vcanbio; Chair, TONACEA CGT Club

 

Patient-Centric Stem Cell New Drug R&D Innovation Practice Session

• Shen Yutian: CEO, Guangzhou Cellgenes Biotechnology Co., Ltd.

 

Advanced Stem Cell Culture Processes Session

• Xiao Shang: Founder and Chairman, Suzhou Youyi Biotechnology Co., Ltd.

• Wu Wei: General Manager, Suzhou Youyi Biotechnology Co., Ltd.

 

In Vivo CAR-T Innovation Session

• Lyu Lulu: Founder and CEO, Juventas Cell Therapy Ltd.

 

Global Small Nucleic Acid Drug Innovation Session

• Liang Zicai: Chairman and CEO, Ribo Life Sciences (Chief Planner)

• Chang Yan: President, InnoStar

• Li Hao: CMO, Kanglonghua

 

Conjugate Drug Innovation Future Session

• Zhou Kaisong: COO, Innovent Biologics; CEO and Board Chair, CBP (Innovent Biologics)

 

Breaking New Ground in Next-Generation Therapies Session

• Liu Jin: CEO, Laurel Venture Capital

• Yuan Jiandong: Chairman, BrightGene Bio-Medical Technology Co., Ltd.

 

Emerging Radiopharmaceuticals Session

• Xu Tao: Founder and CEO, Zhibiotech; Secretary General, TONACEA Radiopharmaceuticals Club

 

Biosimilar Development Session

• Shao Ke: Deputy General Manager, Sinovac Biotech

• Luo Jiali: CEO, Auscan Biopharmaceutical Group

 

Nanobody Drug R&D Session

• Shi Haikun: Founder, Kunyu Bio

 

Non-Clinical Evaluation of Hot-Spot Drugs

• Chen Xiaochun: Deputy General Manager and Co-CSO, Joinn Laboratories

 

AI-Driven Health Industry

 

Intelligent Future – AI for Life Science and Drug Discovery

• Zhang Yan: Co-founder and Senior Vice President, MegaRobo

• Xian Xuan: CIO, GenSci; Dean of AI Drug Discovery Institute

 

AI4S Reshaping Innovative Drug R&D

• Sun Weijie: Founder and CEO, DP Technology

 

AI Industrial Implementation in Innovative Drug R&D Session

• Liang Hongming: Co-founder and Chief Scientific Officer, PhenoX

 

AI Reshaping the Full Chain of Clinical Development Session

• Zhao Shanshan: CEO, JieNa Pharma

 

AI Healthcare Innovation Breakthrough and Future Industrial Layout Session

• Yang Ruirong: Partner, Marathon Venture Partners

 

AI-Powered 4-in-1 Translational Platform to Accelerate Early R&D for Domestic and Overseas Pharma

• Wen Danyi: Founder, Chairman and Executive President, Lidi Bio

 

Pharmaceutical Policies, Regulations and Drug Supervision

 

Changes in US Regulatory Policies and Risk Control

• He Ruyi: President, Shanghai Global Health Innovation Institute

• Du Tao: Chairman, Eglin Pharmaceuticals

 

Decree No. 818 and Translational Application of New Biomedical Technologies Session

• Li Jie: Senior Vice President of Regulatory Affairs, Aeira Health; Board Member, Beijing Economic-Technological Development Area Full-Chain Pharmaceutical Information Research Institute

• Liu Xiao: Vice President, Xingcheng Bio; Chief Brand Officer, TONACEA

 

IIT Regulatory Models and China's Innovation Efficiency Session

• Li Jie: Senior Vice President of Regulatory Affairs, Aeira Health; Board Member, Beijing Economic-Technological Development Area Full-Chain Pharmaceutical Information Research Institute

• Zhang Dan: Chairman, Puxin Bio; Chief Scientist, PUMC Innovation Port

 

Pharmaceutical Production and Supply Chain Management

 

Bioprocessing and Intelligent Manufacturing Session

• Ma Jun: Former Vice President, Junshi Biosciences

• Li Shengying: Executive President, Hanbon Technology

 

Building an Innovation Ecosystem in the Biopharma Upstream Supply Chain Session

• Jia Qijun: Founder and Chairman, Arios

 

Med-Engineering Integration and Innovative Medical Devices

 

Brain-Computer Interface Session

• Hou Jinbiao: Fund Partner, TRIWISE International Capital Management Co., Ltd.

 

International Advanced Drug Delivery Systems / Drug-Device Combinations Session

• Zhang Lijie: Founder, ESCMedTech

• Huang Hua: Director and CEO, ESCMedTech

 

Investment, Financing, IPO and M&A

 

Industrial Securities Session

• Sun Yuanyuan: Executive Deputy Director, Economic and Financial Research Institute, Industrial Securities; Chief Pharmaceutical Analyst

 

Soochow Securities Session

• Zhu Guoguang: Co-Head of Research Institute, Soochow Securities; Chief Pharmaceutical Analyst

• Xiao Hongde: Chief Innovative Drug Analyst, Soochow Securities

 

The Evolution and Beyond of NewCo Session

• Zhu Jielun: Partner, Button Capital

• Wu Jie: MPM Asia Pacific Head / K2 CBO

 

Biopharmaceutical M&A Session

• Wang Yunfan: Founder, Morning Whistle Group

• Deng Jianliang: Partner, Tianhui Capital; Founder, JiaZhe MedTech

 

BLPN Global Biopharma Investor Session

• Wu Baofeng: Founder, SaniMed Science Group

 

Cross-Border Cooperation and China's New Drug Global Expansion

 

Head of Global Partnerships, CPIC 2026

• Yvette Lou: Founding Partner, ZB Consulting

 

Global Development of Pharma Enterprises and Emerging Market Cooperation Session

• Hong Tan: Managing Director, Legend Capital

• Yan Lian: CEO, Rxilient

 

BRICS Session: Deepening Global Multi-Market Presence, Exporting Chinese New Drug Value Across the Full Chain

• Wang Jing: Executive Director and Chief Commercial Officer, CanSino Biologics

 

China-Europe Health Industry Session

• Andreas Penk: Co-founder and CEO, EBT; former President of Pfizer China

• Zhang Fenping: General Manager, GenOway

 

China-Japan Cooperation Session: Leveraging the Japanese Market to Drive Globalization Strategy

• Keiji Kawamoto: Representative, Kawamoto BioBusiness Partners; Senior Advisor, Shanghai Deband Law Firm (Shanghai)

• Dong Ruiping: Founder, RealOne Medicines

• Niu Zhengqian: President, Tokyo Sebiland Health Technology Co., Ltd.

 

China-US Cooperation Session: Leveraging China's Innovation to Accelerate Global Drug R&D

• Gao Zhenghong: COO and Co-founder, Uni-Pioneers BioMed Inc.

• Jiawei Tang: COO, GB-Partner

 

North America-China Innovative Drug Industry Cooperation

• Bo Zhiquan: International Applied Technology Research Institute (IATRI)

• Zhao Yingchun: Operating Partner, BioInno; Vice President, SAPA-DC; Director of Pharmacy, IATRI

 

Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises Session

• Li Xiang: Partner, Fangda Partners

 

JunHe Law Firm Session: New Models of Pharmaceutical Cross-Border Cooperation

• Zhao Hao: Partner, JunHe Law Firm

 

From IP to BD: The Dealmaking Power of Chinese Innovative Drugs Session

• Tang Huadong, Guo Xiaoxing, Huang Xiaolin: Partners, Merits & Tree Law Firm

 

Global BD Collaboration for Innovative Drugs Session 1-2-3

• Dai Han: Chief Innovation Officer, Viva Biotech; Head, Viva BioInnovator

• Zhang Zhimin: Mentor, QB3/Bakar Biotech Incubator, UC Berkeley

• Wang Min: Partner, PBNY

• Ji Xiaohui: CEO, Elpiscience

 

Building Cross-Border Biotech Innovation Ecosystems as a New Engine for Industrial Transformation Session

• Sally Sha: Vice President, China Head, ELPIS Biopharmaceuticals

 

Vaccine Innovation and Globalization Session

• Zhang Jiguo: General Manager, Fosun Vaccine

 

Hong Kong Globalization Opportunities Session

• Shen Chenyi: Director of Secretariat, Hong Kong Chinese General Chamber of Commerce

• Liao Lifang: Chief Executive, Hong Kong Biomedical Innovation Association

 

Innovation Ecosystem and Innovation Models

 

The Innovation Transformation Path of Traditional Pharma

• Cheng Genhong: Fellow of the American Academy of Microbiology; Distinguished Professor, Guangzhou Laboratory; Advisor, Guangzhou Pharmaceutical Group

 

Biomedical Industrial Park Development Session

• Sun Xiaomeng: General Manager, Shanghai Minhang Biomedical Industry Development Co., Ltd.

 

USTC / China-Japan Pharmaceutical and New Materials Innovation Session – USTC Original Innovation Power

• Hu Yonghan: CTO, Sinovive

 

Western Returned Scholars Association Session: Innovation Translation and Global Competitiveness of Chinese Hospitals

• Dong Zengjun: Rotating President, Western Returned Scholars Association (USA Chapter)

• Li Bin: Vice President, Shanghai Overseas Returned Scholars Association; President, Biomedical Branch; Deputy Director, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine

 

Chinese Biotech: Integrated R&D, Manufacturing & Commercialization vs. Specialized Division of Labor

• Tao Qiucheng: Vice President of Investment, Yatai Capital

 

Women Leading the Future of Healthcare Innovation Session

• Jiawei Tang: COO, GB-Partner

 

Roadshow Session

• Chen Feng: Founder and CEO, Bio-Link Capital